Peakadilly NV, the predictive protein biomarkers company, has announced that it has changed its name to Pronota NV, effective immediately.
Following the recent close of series A financing at €14.5 million ($18.4 million), the company is increasing capacity of both equipment and employees, and the name change is part of its positioning to become recognised as a major player in protein biomarker discovery and application.
Pronota has an innovative protein biomarker discovery technology, which it expects will transform the potential of protein biomarkers in molecular diagnostics and drug discovery and development.
The Company is commercialising its proprietary MASStermind™ technology, which allows the analysis of proteomes from biological samples, including blood, at unprecedented depth and speed. Pronota has already secured a series of granted patents and revenue-generating projects with pharmaceutical companies.
Protein biomarkers are useful not only for diagnosis of diseases such as cancer, cardiovascular diseases and disorders of the central nervous system, but also for understanding disease mechanisms, and as a basis for the development of therapeutics.
Pronota is using its protein biomarkers to develop its own disease screens and pharmacodiagnostic products, which the company expects will play a key role in the development of disease diagnostics and personalised medicine.
Commenting on the name change Nick McCooke, CEO said: “Pronota’s unique protein biomarker discovery technology represents a significant advance over other approaches and the new name reflects our strategy to become recognised as leading innovators in the protein biomarkers field. This name change supports the Company’s commercial development, as we move forward to develop a new generation of molecular diagnostics.”